|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar
|
|
2
|
Takeno S, Noguchi T, Kikuchi R, Sato T,
Uchida Y and Yokoyama S: Analysis of the survival period in
resectable stage IV gastric cancer. Ann Surg Oncol. 8:215–221.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bouriez D, Giraud J, Gronnier C and Varon
C: Efficiency of All-Trans Retinoic Acid on Gastric Cancer: A
Narrative Literature Review. Int J Mol Sci. 19:192018. View Article : Google Scholar
|
|
4
|
Li X, Liu Y, Cao B, Liu B, Bai T, Li X,
Mei L and Che X: Metastatic lymph node ratio and prognosis of
gastric cancer at different pT stages. Hepatogastroenterology.
62:507–511. 2015.PubMed/NCBI
|
|
5
|
Wang Q, Chen Q, Zhu L, Chen M, Xu W,
Panday S, Wang Z, Li A, Røe OD, Chen R, et al: JWA regulates
TRAIL-induced apoptosis via MARCH8-mediated DR4 ubiquitination in
cisplatin-resistant gastric cancer cells. Oncogenesis. 6:e3532017.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu LP, Sheng XP, Shuai TK, Zhao YX, Li B
and Li YM: Helicobacter pylori promotes invasion and metastasis of
gastric cancer by enhancing heparanase expression. World J
Gastroenterol. 24:4565–4577. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xie Y, Jin P, Sun X, Jiao T, Zhang Y, Li Y
and Sun M: SIX1 is upregulated in gastric cancer and regulates
proliferation and invasion by targeting the ERK pathway and
promoting epithelial-mesenchymal transition. Cell Biochem Funct.
Oct 31–2018, Epub ahead of print. View
Article : Google Scholar
|
|
8
|
Song Y, Mu L, Han X, Liu X and Fu S: siRNA
targeting stathmin inhibits invasion and enhances chemotherapy
sensitivity of stem cells derived from glioma cell lines. Acta
Biochim Biophys Sin (Shanghai). 46:1034–1040. 2014. View Article : Google Scholar
|
|
9
|
Wang F, Xuan XY, Yang X, Cao L, Pang LN,
Zhou R, Fan QX and Wang LX: Stathmin is a marker of progression and
poor prognosis in esophageal carcinoma. Asian Pac J Cancer Prev.
15:3613–3618. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu X, Liu H, Liang J, Yin B, Xiao J, Li
J, Feng D and Li Y: Stathmin is a potential molecular marker and
target for the treatment of gastric cancer. Int J Clin Exp Med.
8:6502–6509. 2015.PubMed/NCBI
|
|
11
|
Lu Y, Liu C, Cheng H, Xu Y, Jiang J, Xu J,
Long J, Liu L and Yu X: Stathmin, interacting with Nf-κB, promotes
tumor growth and predicts poor prognosis of pancreatic cancer. Curr
Mol Med. 14:328–339. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ke B, Wu LL, Liu N, Zhang RP, Wang CL and
Liang H: Overexpression of stathmin 1 is associated with poor
prognosis of patients with gastric cancer. Tumour Biol.
34:3137–3145. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Byrne FL, Yang L, Phillips PA, Hansford
LM, Fletcher JI, Ormandy CJ, McCarroll JA and Kavallaris M:
RNAi-mediated stathmin suppression reduces lung metastasis in an
orthotopic neuroblastoma mouse model. Oncogene. 33:882–890. 2014.
View Article : Google Scholar
|
|
14
|
Lu Y, Liu C, Xu YF, Cheng H, Shi S, Wu CT
and Yu XJ: Stathmin destabilizing microtubule dynamics promotes
malignant potential in cancer cells by epithelial-mesenchymal
transition. Hepatobiliary Pancreat Dis Int. 13:386–394. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
16
|
Moriyama T, Ito A, Omote S, Miura Y and
Tsumoto H: Heat Resistant Characteristics of Major Royal Jelly
Protein 1 (MRJP1) Oligomer. PLoS One. 10:e01191692015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang ZQ, Cai Q, Hu L, He CY, Li JF, Quan
ZW, Liu BY, Li C and Zhu ZG: Long noncoding RNA UCA1 induced by SP1
promotes cell proliferation via recruiting EZH2 and activating AKT
pathway in gastric cancer. Cell Death Dis. 8:e28392017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pan T, Chen W, Yuan X, Shen J, Qin C and
Wang L: miR-944 inhibits metastasis of gastric cancer by preventing
the epithelial-mesenchymal transition via MACC1/Met/AKT signaling.
FEBS Open Bio. 7:905–914. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim JW, Lee HS, Nam KH, Ahn S, Kim JW, Ahn
SH, Park DJ, Kim HH and Lee KW: PIK3CA mutations are associated
with increased tumor aggressiveness and Akt activation in gastric
cancer. Oncotarget. 8:90948–90958. 2017.PubMed/NCBI
|
|
20
|
Wang C, Jiang J, Ji J, Cai Q, Chen X, Yu
Y, Zhu Z and Zhang J: PKM2 promotes cell migration and inhibits
autophagy by mediating PI3K/AKT activation and contributes to the
malignant development of gastric cancer. Sci Rep. 7:28862017.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Song Y, Li ZX, Liu X, Wang R, Li LW and
Zhang Q: The Wnt/β-catenin and PI3K/Akt signaling pathways promote
EMT in gastric cancer by epigenetic regulation via H3 lysine 27
acetylation. Tumour Biol. 39:10104283177126172017. View Article : Google Scholar
|
|
22
|
Zhang X, Tang J, Zhi X, Xie K, Wang W, Li
Z, Zhu Y, Yang L, Xu H and Xu Z: Correction: miR-874 functions as a
tumor suppressor by inhibiting angiogenesis through STAT3/VEGF-A
pathway in gastric cancer. Oncotarget. 8:295352017.PubMed/NCBI
|
|
23
|
You W, Tang Q, Zhang C, Wu J, Gu C, Wu Z
and Li X: IL-26 promotes the proliferation and survival of human
gastric cancer cells by regulating the balance of STAT1 and STAT3
activation. PLoS One. 8:e635882013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zheng L, Chen J, Zhou Z and He Z:
Knockdown of long non-coding RNA HOXD-AS1 inhibits gastric cancer
cell growth via inactivating the JAK2/STAT3 pathway. Tumour Biol.
39:10104283177053352017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xu YY, Guo M, Yang LQ, Zhou F, Yu C, Wang
A, Pang TH, Wu HY, Zou XP, Zhang WJ, et al: Regulation of CD44v6
expression in gastric carcinoma by the IL-6/STAT3 signaling pathway
and its clinical significance. Oncotarget. 8:45848–45861.
2017.PubMed/NCBI
|
|
26
|
Merchant JL: What lurks beneath: IL-11,
via Stat3, promotes inflammation-associated gastric tumorigenesis.
J Clin Invest. 118:1628–1631. 2008.PubMed/NCBI
|
|
27
|
Zgodziński W, Grywalska E, Surdacka A,
Zinkiewicz K, Majewski M, Szczepanek D, Wallner G and Roliński J:
Surface CD200 and CD200R antigens on lymphocytes in advanced
gastric cancer: A new potential target for immunotherapy. Arch Med
Sci. 14:1271–1280. 2018. View Article : Google Scholar
|
|
28
|
Jin X, Zhu Z and Shi Y: Metastasis
mechanism and gene/protein expression in gastric cancer with
distant organs metastasis. Bull Cancer. Oct 8–2014, Epub ahead of
print. PubMed/NCBI
|
|
29
|
Han ZX, Wang HM, Jiang G, Du XP, Gao XY
and Pei DS: Overcoming paclitaxel resistance in lung cancer cells
via dual inhibition of stathmin and Bcl-2. Cancer Biother
Radiopharm. 28:398–405. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wosnitzer MS, Domingo-Domenech J,
Castillo-Martin M, Ritch C, Mansukhani M, Petrylack DP, Benson MC,
McKiernan JM and Cordon-Cardo C: Predictive value of microtubule
associated proteins tau and stathmin in patients with nonmuscle
invasive bladder cancer receiving adjuvant intravesical taxane
therapy. J Urol. 186:2094–2100. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Werner HM, Trovik J, Halle MK, Wik E,
Akslen LA, Birkeland E, Bredholt T, Tangen IL, Krakstad C and
Salvesen HB: Stathmin protein level, a potential predictive marker
for taxane treatment response in endometrial cancer. PLoS One.
9:e901412014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kouzu Y, Uzawa K, Koike H, Saito K,
Nakashima D, Higo M, Endo Y, Kasamatsu A, Shiiba M, Bukawa H, et
al: Overexpression of stathmin in oral squamous-cell carcinoma:
Correlation with tumour progression and poor prognosis. Br J
Cancer. 94:717–723. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Miceli C, Tejada A, Castaneda A and Mistry
SJ: Cell cycle inhibition therapy that targets stathmin in in vitro
and in vivo models of breast cancer. Cancer Gene Ther. 20:298–307.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yuan SF, Chen WJ, Zhu LJ, Zheng WE, Chen H
and Xiong JP: Effects of monoclonal antibodies against human
stathmin combined with paclitaxel on proliferation of the QG-56
human lung carcinoma cell line. Asian Pac J Cancer Prev.
13:2967–2971. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
D'Andrea S, Berton S, Segatto I, Fabris L,
Canzonieri V, Colombatti A, Vecchione A, Belletti B and Baldassarre
G: Stathmin is dispensable for tumor onset in mice. PLoS One.
7:e455612012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ying L, Su D, Zhu J, Ma S, Katsaros D and
Yu H: Genotyping of stathmin and its association with clinical
factors and survival in patients with ovarian cancer. Oncol Lett.
5:1315–1320. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Pucci S, Bonanno E, Sesti F, Mazzarelli P,
Mauriello A, Ricci F, Zoccai GB, Rulli F, Galatà G and Spagnoli LG:
Clusterin in stool: A new biomarker for colon cancer screening? Am
J Gastroenterol. 104:2807–2815. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Flanagan L, Whyte L, Chatterjee N and
Tenniswood M: Effects of clusterin over-expression on metastatic
progression and therapy in breast cancer. BMC Cancer. 10:1072010.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Rizzi F and Bettuzzi S: The clusterin
paradigm in prostate and breast carcinogenesis. Endocr Relat
Cancer. 17:R1–R17. 2010. View Article : Google Scholar
|
|
40
|
Bi J, Guo AL, Lai YR, Li B, Zhong JM, Wu
HQ, Xie Z, He YL, Lv ZL, Lau SH, et al: Overexpression of clusterin
correlates with tumor progression, metastasis in gastric cancer: A
study on tissue microarrays. Neoplasma. 57:191–197. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Xiu P, Xu Z, Liu F, Li Z, Li T, Zou F, Sun
X and Li J: Downregulating sCLU enhances the sensitivity of
hepatocellular carcinoma cells to gemcitabine by activating the
intrinsic apoptosis pathway. Dig Dis Sci. 59:1798–1809. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wang C, Jin G, Jin H, Wang N, Luo Q, Zhang
Y, Gao D, Jiang K, Gu D, Shen Q, et al: Clusterin facilitates
metastasis by EIF3I/Akt/MMP13 signaling in hepatocellular
carcinoma. Oncotarget. 6:2903–2916. 2015.PubMed/NCBI
|
|
43
|
Gong F, Peng X, Sang Y, Qiu M, Luo C, He
Z, Zhao X and Tong A: Dichloroacetate induces protective autophagy
in LoVo cells: Involvement of cathepsin D/thioredoxin-like protein
1 and Akt-mTOR-mediated signaling. Cell Death Dis. 4:e9132013.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Huang WW, Tsai SC, Peng SF, Lin MW, Chiang
JH, Chiu YJ, Fushiya S, Tseng MT and Yang JS: Kaempferol induces
autophagy through AMPK and AKT signaling molecules and causes G2/M
arrest via downregulation of CDK1/cyclin B in SK-HEP-1 human
hepatic cancer cells. Int J Oncol. 42:2069–2077. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhang Y, Huang W, Ran Y, Xiong Y, Zhong Z,
Fan X, Wang Z and Ye Q: miR-582-5p inhibits proliferation of
hepatocellular carcinoma by targeting CDK1 and AKT3. Tumour Biol.
36:8309–8316. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Tibes R, McDonagh KT, Lekakis L,
Bogenberger JM, Kim S, Frazer N, Mohrland S, Bassett D, Garcia R,
Schroeder K, et al: Phase I study of the novel Cdc2/CDK1 and AKT
inhibitor terameprocol in patients with advanced leukemias. Invest
New Drugs. 33:389–396. 2015. View Article : Google Scholar
|
|
47
|
Li B, Xu W, Luo C, Gozal D and Liu R:
VEGF-induced activation of the PI3-K/Akt pathway reduces mutant
SOD1-mediated motor neuron cell death. Brain Res Mol Brain Res.
111:155–164. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhang B, Zhang K, Liu Z, Hao F, Wang M, Li
X, Yin Z and Liang H: Secreted clusterin gene silencing enhances
chemo-sensitivity of a549 cells to cisplatin through AKT and ERK1/2
pathways in vitro. Cell Physiol Biochem. 33:1162–1175. 2014.
View Article : Google Scholar
|
|
49
|
Ma X and Bai Y: IGF-1 activates the
P13K/AKT signaling pathway via upregulation of secretory clusterin.
Mol Med Rep. 6:1433–1437. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Shim YJ, Kang BH, Jeon HS, Park IS, Lee
KU, Lee IK, Park GH, Lee KM, Schedin P and Min BH: Clusterin
induces matrix metal-loproteinase-9 expression via ERK1/2 and
PI3K/Akt/NF-κB pathways in monocytes/macrophages. J Leukoc Biol.
90:761–769. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Yadav P, Selvaraj BT, Bender FL, Behringer
M, Moradi M, Sivadasan R, Dombert B, Blum R, Asan E, Sauer M, et
al: Neurofilament depletion improves microtubule dynamics via
modulation of Stat3/stathmin signaling. Acta Neuropathol.
132:93–110. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Morris EJ, Kawamura E, Gillespie JA, Balgi
A, Kannan N, Muller WJ, Roberge M and Dedhar S: Stat3 regulates
centrosome clustering in cancer cells via Stathmin/PLK1. Nat
Commun. 8:152892017. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Ng DC, Lin BH, Lim CP, Huang G, Zhang T,
Poli V and Cao X: Stat3 regulates microtubules by antagonizing the
depolymerization activity of stathmin. J Cell Biol. 172:245–257.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Verma NK, Dourlat J, Davies AM, Long A,
Liu WQ, Garbay C, Kelleher D and Volkov Y: STAT3-stathmin
interactions control microtubule dynamics in migrating T-cells. J
Biol Chem. 284:12349–12362. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Ebrahimpour S and Saadat I: Association of
CAT C-262T and SOD1 A251G single nucleotide polymorphisms
susceptible to gastric cancer. Mol Biol Res Commun. 3:223–229.
2014.PubMed/NCBI
|
|
56
|
Kantsaliev AL, Kozyreva EA, Kushlinskiĭ
NE, Rottenberg VI, Klimenkov AA and Vasil'ev AV: Cathepsin D
activity in gastric cancer. Vopr Onkol. 40:40–46. 1994.In
Russian.
|
|
57
|
Saku T, Sakai H, Tsuda N, Okabe H, Kato Y
and Yamamoto K: Cathepsins D and E in normal, metaplastic,
dysplastic, and carcinomatous gastric tissue: An
immunohistochemical study. Gut. 31:1250–1255. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Gao SY, Li J, Qu XY, Zhu N and Ji YB:
Downregulation of Cdk1 and cyclinB1 expression contributes to
oridonin-induced cell cycle arrest at G2/M phase and growth
inhibition in SGC-7901 gastric cancer cells. Asian Pac J Cancer
Prev. 15:6437–6441. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Zeng Q, Zhao Y, Yang Y, Chen XX, Wang G,
Zhang P, Cui Y, Su S and Li K: Expression of Cystatin C in human
stomach neoplasms. Mol Med Rep. 3:607–611. 2010.
|
|
60
|
Allgayer H, Babic R, Grützner KU, Beyer
BC, Tarabichi A, Wilhelm Schildberg F and Heiss MM: An
immunohistochemical assessment of cathepsin D in gastric carcinoma:
Its impact on clinical prognosis. Cancer. 80:179–187. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Lee MH, Cho Y, Kim DH, Woo HJ, Yang JY,
Kwon HJ, Yeon MJ, Park M, Kim SH, Moon C, et al: Menadione induces
G2/M arrest in gastric cancer cells by down-regulation of CDC25C
and proteasome mediated degradation of CDK1 and cyclin B1. Am J
Transl Res. 8:5246–5255. 2016.
|
|
62
|
Liu H, Lu J, Hua Y, Zhang P, Liang Z, Ruan
L, Lian C, Shi H, Chen K and Tu Z: Targeting heat-shock protein 90
with ganetespib for molecularly targeted therapy of gastric cancer.
Cell Death Dis. 6:pp. e15952015, View Article : Google Scholar : PubMed/NCBI
|
